本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 私募大V就是私募行业内，在微博、雪球等社交平台拥有大量粉丝的"意见领袖"，同时也时刻面临着业绩和口碑的双重考验。有的私募大V本身 是私募基金的实控人、基金经理或核心投研人员，部分私募大V"身兼多职"，如东方港湾但斌、林园投资林园、半夏投资李蓓。 截至今年 7月底，私募排排网有信息展示的私募大V共有74位，同时担任实控人的有41位。 从所属公司来看，百亿私募共有8家，投资模式为主 观的私募占比接近80%。从粉丝数（或关注度）来看，核心账号粉丝达到百万级别的有东方港湾但斌、日斗投资王文、神农投资陈宇等。（ 点 此领取全名单 ） | 排序 | 大V核心账号ID | 真实姓名 | 关联私募 | 私募投资 模式 | 更新平台 | 核心账号 粉丝数/ | 私募规模 | 是否为 实控 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 世状況 | | | | 1 | 但斌 | 但斌 | 东方港湾 | 主观 | 雪球 | 千万+ | 100亿以上 | 是 | | 2 | ...

Group 1: Company Overview - Zhonghui Biotech officially listed on the Hong Kong Stock Exchange at an issue price of HKD 12.9 per share, closing at HKD 33.28, a 157.98% increase, with a market capitalization exceeding HKD 13 billion [2] - The company plans to use the funds raised from the IPO for domestic and international registration of core products, clinical advancement of vaccines in development, upgrading production capabilities, and technology platform iteration [2][4] Group 2: Financial Performance - Zhonghui Biotech reported revenues of CNY 52.168 million in 2023 and CNY 260 million in 2024, with a net loss narrowing from CNY 4.25 billion in 2023 to CNY 2.59 billion in 2024 [4][5] - The company's first commercialized product, a quadrivalent influenza vaccine, contributed significantly to revenue, generating CNY 52.2 million in 2023 and CNY 260 million in 2024 [5] Group 3: Market Environment - The domestic influenza vaccine market is highly competitive, with 26 types of vaccines already on the market and 19 in clinical development [5][6] - The average bidding price for influenza vaccines in China has decreased from CNY 126 per dose in 2022 to CNY 93 in 2024, indicating a price war that could stimulate market demand [6][7] Group 4: Industry Trends - The Chinese vaccine market is projected to grow from CNY 535 billion in 2019 to CNY 1,205 billion in 2023, with expectations to reach CNY 3,431 billion by 2032 [8] - The industry faces challenges such as product homogeneity and insufficient vaccination willingness, leading to significant performance declines for many vaccine companies in 2024 [8][9] Group 5: Strategic Initiatives - Zhonghui Biotech is focusing on expanding its pipeline, which includes rabies vaccines, pneumococcal vaccines, shingles vaccines, RSV vaccines, and monkeypox vaccines [9][10] - The company is also pursuing international expansion, with plans to submit product registration applications in various countries, including Indonesia, Thailand, and Canada [11]

Group 1 - The total amount of public fund self-purchases in 2025 has reached 747 million yuan, with 21 public funds announcing self-purchases this year [2][3] - Southern Fund leads with a self-purchase amount of 230 million yuan, setting a record for the largest self-purchase this year [2][3] - Other notable self-purchases include 180 million yuan from Jianxin Fund and 1.73 billion yuan in total from Jianxin Fund from Q4 2024 to Q1 2025, both with a holding period of at least one year [2][3] Group 2 - The net subscription amount for public funds this year has reached 13.713 billion yuan, with equity funds accounting for 1.752 billion yuan, representing 12.78% of the total [3][4] - In terms of net subscriptions, Invesco Great Wall Fund and China Europe Fund rank first with net subscription amounts of 3.039 billion yuan and 2.165 billion yuan, respectively [4][5] - Other funds with significant net subscriptions include ICBC Credit Suisse Fund with over 1 billion yuan and Southern Fund with 823 million yuan [4][5] Group 3 - Morgan Stanley Fund highlights that A-shares remain undervalued compared to overseas markets, with significant expansion potential, particularly in technology growth sectors such as AI applications and semiconductors [5][6] - The domestic macro risks are considered manageable, with a clear trend of declining risk-free rates and increased capital inflow into the market, maintaining a positive outlook for A-shares [6] - Hai Fu Tong Fund notes the effects of "anti-involution" policies, with expectations for PPI to stabilize and recover, suggesting a favorable market performance for growth and TMT styles in the short term [6]

今日，恒生港股通创新药指数修订编制方案正式生效，明确剔除医药外包企业（CXO），成为ETF 跟踪指数中首批"纯度"100%的创新药指数。此次调整后，指数成份股全部为创新药企，更精准反映行 业发展趋势。 此次修订剔除了5家CXO公司，其原权重合计约20%，且年内涨幅不及指数整体表现。回测显示， 剔除CXO后，2023年指数发布日以来、2024年、2025年初至今，指数业绩表现均更优，且自2023年7月 10日指数发布以来，指数修订后年化收益率超47%，夏普比率也更高。 每日经济新闻 （责任编辑：董萍萍 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 近年来，我国创新药产业发展成果显著，管线储备跃居全球第二，吸引跨国药企大幅增加专利采 购。其在国际市场竞争力的增强，也成为股票市场重新定价我国创新药资产的重要依据，恒生港股通创 新药指数年内累计涨幅约100%。作为唯一跟踪该指数的产品，恒生创新药ETF（15 ...

今天，A股三大指数高开高走，创业板指领涨，上证指数、深证成指盘中均创年内新高，最高分别触及3656.85点、11311.88点。 截至收盘，沪指涨0.34%，深成指涨1.46%，创业板指涨1.96%。全市场成交额约1.85万亿元，较上个交易日放量1136亿元。全市场超4100只个股上涨。 板块方面，PEEK材料、锂矿、CPO、PCB等板块涨幅居前，银行、黄金、影视、工程机械等板块跌幅居前。 从热门个股来看，今天，PEEK材料概念股中欣氟材收获"5天4板"。算力硬件股胜宏科技创历史新高。 锂矿股集体大涨，盛新锂能等多股涨停。券商股走强，东方财富全天成交额110.44亿元，居全市场第一。新疆交建一字涨停，截至收盘封单量超70万手。 多重利好支撑 消息面上，近期，市场迎来多个利好支撑。 一是国家统计局8月9日发布数据显示，7月份，扩内需政策效应持续显现，居民消费价格指数（CPI）环比由上月下降0.1%转为上涨0.4%，同比持平，扣 除食品和能源价格的核心CPI同比上涨0.8%，涨幅连续3个月扩大。国家统计局城市司首席统计师董莉娟表示："扩内需政策效应持续显现，消费领域价格 继续呈现积极变化。" 二是重要产业支持政策 ...

Market Performance - The Shanghai Composite Index rose by 0.34% to close at 3647.55, marking six consecutive days of gains, while the Shenzhen Component Index increased by 1.46% to 11291.43, and the ChiNext Index surged by 1.96% to 2379.82, with both the Shanghai and Shenzhen indices reaching new highs for the year [2][3]. Sector Performance - Various industry sectors experienced gains, with PEEK materials, lithium mining, CPO, and consumer electronics leading the increases. Notably, stocks like Shuangyi Technology and Chaojie Co. hit the daily limit of 20% increase, while others like Zhongxin Fluorine Materials and Jinfat Technology also reached their daily limit [5]. - The lithium mining sector remained strong, with companies such as Shengxin Lithium Energy and Jiangte Electric achieving daily limit increases, and Ganfeng Lithium also hitting the daily limit [6]. - Conversely, the precious metals sector faced adjustments, with all stocks in this category declining. Notably, Chifeng Gold fell over 5%, while Western Gold and Shandong Gold dropped more than 4% [7]. Capital Flow - Main capital inflows were observed in the electronics, computer, power equipment, and pharmaceutical sectors, while outflows were noted in banking, public utilities, and oil and petrochemicals. Specific stocks like Kweichow Moutai, Dongfang Wealth, and Zhongji Xuchuang saw net inflows of 9.73 billion, 8.82 billion, and 8.22 billion respectively [8]. - On the outflow side, China Shipbuilding, Ningbo Yunsen, and Huayin Electric faced net sell-offs of 9.32 billion, 6.87 billion, and 5.57 billion respectively [9]. Institutional Insights - Guotai Junan noted that the market is currently in a critical phase of intraday tug-of-war between bulls and bears. They suggest that favorable policies and increased trading volume could lead to a breakthrough of previous highs, with continued optimism for technology growth, finance, and certain cyclical sectors [10]. - CITIC Securities highlighted the acceleration of industry rotation and recommended focusing on low-position niche segments in new tracks, particularly in defense, AI computing, semiconductors, humanoid robots, non-ferrous metals, transportation, brokerage, and innovative pharmaceuticals [10].

Core Viewpoint - The article highlights the significant rise of Chinese innovative drugs in the market, exemplified by the explosive debut of Zhonghui Biopharma-B, which saw a surge of nearly 160% on its first trading day, reflecting a broader trend of growth in the innovative drug sector in China [1][2][6]. Group 1: Zhonghui Biopharma-B Performance - Zhonghui Biopharma-B's stock price increased by 169.7% on its debut, closing with a nearly 160% gain [1][2]. - The company set a lower limit price of HKD 12.9 per share, raising a net amount of HKD 383 million [6]. - The public offering was oversubscribed by 4006.64 times, freezing HKD 210 billion in capital, making it the most oversubscribed biotech stock in Hong Kong this year [6]. Group 2: Growth of Innovative Drugs in China - The share of China's innovative drug BD (business development) transactions in the global market has increased from 10.8% in 2015 to an estimated 52.5% as of August 8, 2023 [9]. - The market size of innovative drugs in China reached CNY 679 billion in 2022, with projections to exceed CNY 1 trillion by 2026 and reach CNY 1.12 trillion by 2027 [9]. - The proportion of innovative drugs in the Chinese pharmaceutical market was 41% in 2022, expected to rise to 50% by 2026 and 51% by 2027 [9]. Group 3: Policy Support for Innovation - The National Healthcare Security Administration (NHSA) has held five meetings focused on supporting innovative drugs and medical devices, emphasizing a complete chain from research and development to payment [10]. - The NHSA's stance is to support genuine innovation while rejecting pseudo-innovation, which is expected to accelerate the global presence of Chinese innovative drugs and benefit patients [10].

Group 1 - The adjustment of the Hang Seng Hong Kong Stock Connect Innovative Drug Index has officially taken effect, removing CXO to create a "pure" 100% innovative drug index, which more accurately reflects the overall performance of China's innovative pharmaceutical companies [1] - Historical performance of the index is expected to improve significantly after the removal of CXO, with an annualized return exceeding 47% and a higher Sharpe ratio since the index's inception [1] - Several Hong Kong innovative drug companies have reported positive mid-year results, and the outbound licensing of domestic innovative drugs has accelerated, with License out amounts reaching nearly $80 billion from January to July, a year-on-year increase of over 160% [1] Group 2 - Recent high-value licensing agreements have been reached by companies such as CSPC Pharmaceutical Group and Hansoh Pharmaceutical [1] - There has been a notable increase in capital inflow into Hong Kong innovative drug-related ETFs, with the Hang Seng Innovative Drug ETF (159316) experiencing net inflows for nine consecutive weeks, reaching a scale of over 1 billion yuan, doubling from a month ago [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only ETF product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which is expected to better assist investors in seizing industry development opportunities following the index revision [1]

Group 1 - The launch of the National Smart Medical Insurance Competition will enhance the efficiency of innovative drug research and development, with open medical insurance data aiding companies in accurately identifying clinical needs, shortening R&D cycles, and reducing costs [1] - The competition promotes cross-industry collaboration among pharmaceutical companies, technology firms, and research institutions, facilitating resource integration and innovation synergy, thereby accelerating the transition of innovative drugs from the laboratory to clinical application [1] - In the long term, the innovative drug sector possesses high growth potential, with the deepening application of medical insurance data expected to improve both the quantity and quality of innovative drugs, which can capture significant market share and pricing power post-approval [1] Group 2 - The reactivation of the dual financing channels of the Sci-Tech Innovation Board and Hong Kong's 18A model enhances the full-cycle financing capabilities of pharmaceutical companies, while new regulations on traditional Chinese medicine pieces will accelerate industry consolidation, benefiting leading firms and distribution channels [1] - The 11th batch of centralized procurement highlights policy determination, further emphasizing the investment value of innovative drugs [1] - The Guotai Sci-Tech Innovative Drug ETF (589720) tracks the Sci-Tech Innovative Drug Index (950161), which can experience daily fluctuations of up to 20%, focusing on representative companies in the new drug development sector, primarily in biomedicine and chemical pharmaceuticals [1]

Group 1 - The core viewpoint of the articles highlights the significant growth in global pharmaceutical transactions, particularly driven by China's contribution, with a 32% increase in transaction volume and a 58% surge in total transaction value in the first half of 2025 [1] - China's innovative drugs are gaining global recognition, with nearly 50% of the transaction value attributed to the country, indicating a positive trend in the international market for Chinese pharmaceuticals [1] - The domestic healthcare insurance bureau is promoting a pricing mechanism for innovative drug launches, and there is a revival in financing for innovative drugs in both primary and secondary markets, as evidenced by Hong Kong-listed innovative drug companies experiencing first-day gains exceeding 50% [1] Group 2 - The GLP-1 weight loss sector is rapidly advancing, with notable approvals and commercialization efforts from companies like Eli Lilly and Innovent Biologics, indicating a robust market for obesity treatments [1] - The overseas GLP-1 market is showing stable growth, with the transaction value in the weight loss sector expected to reach 1.5 times that of 2024 in the first half of 2025 [1] - The CXO industry is gradually recovering after a period of consolidation, with the total upfront payments for License-out transactions surpassing primary market financing for the first time in the first half of 2025 [1] Group 3 - TCE technology (T-cell bridging technology) is being widely applied in the dual and multi-antibody fields, with Johnson & Johnson reporting excellent clinical data for its tri-antibody product, and domestic company SIM0500 achieving licensing [1] - Breakthroughs in the autoimmune sector are being made, with companies like Rongchang Biologics advancing their products into Phase III trials and Lizhu Pharmaceutical reporting positive clinical efficacy data [1]